Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when WST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsWest Pharmaceutical shareholders reject independent board chair proposal at annual meeting
Filed May 5, 2026 · Period ending May 4, 2026 · ~1 min read
Key Changes
-
medium
Shareholders voted down a proposal requiring an independent board chair (46% for, 54% against), allowing current leadership structure to continue. This was the only contested item at the meeting.
Item 5.07 verify on EDGAR → -
low
All 11 director nominees elected to one-year terms with majority support, providing board continuity through 2027 annual meeting.
Item 5.07 verify on EDGAR → -
low
Executive compensation approved with 94% shareholder support (60.1M for vs 3.8M against), indicating satisfaction with pay practices.
Item 5.07 verify on EDGAR → -
low
PricewaterhouseCoopers ratified as auditor for fiscal 2026 with 88% approval, maintaining audit continuity.
Item 5.07 verify on EDGAR →
Summary
West Pharmaceutical held its 2026 annual shareholder meeting virtually on May 4, with strong participation representing 92% of outstanding shares. The headline result was shareholders' rejection of a proposal to require an independent board chair, with 54% voting against the measure. This means the company will maintain its current board leadership structure without a mandated separation of chair and CEO roles.
The meeting was otherwise routine, with all 11 directors re-elected and both executive compensation and the auditor appointment receiving strong approval. The 94% support for executive pay suggests shareholders are satisfied with how management is compensated relative to company performance. For retail investors, the key takeaway is governance continuity. Watch for any renewed shareholder activism on board independence in future proxy seasons, as the 46% support for the independent chair proposal indicates meaningful shareholder interest in enhanced board oversight.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
West Pharmaceutical held its 2026 Annual Meeting on May 4, 2026, electing 11 directors, approving executive compensation, ratifying auditor, and rejecting a shareholder proposal on independent board chair.
Show 3 minor / wording changes
Added in current filing · verify on EDGAR →
West Pharmaceutical Services, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026. The four proposals that were voted on at the Annual Meeting are described in detail in the Company’s 2026 Proxy Statement. As of the record date, February 27, 2026, there were 72,081,610 shares of the Company’s common stock outstanding. A total of 66,193,322 shares, representing 91.83% of the Company’s common stock outstanding, were represented at the Annual Meeting.
The company held its annual shareholder meeting virtually with strong participation of 91.83% of outstanding shares. Four proposals were voted on, including director elections, executive compensation approval, auditor ratification, and a shareholder proposal regarding board leadership structure.
Added in current filing · verify on EDGAR →
Proposal 1: The eleven nominees, as set forth below and in the Company’s 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.
All eleven director nominees were elected to serve one-year terms until the 2027 Annual Meeting. The nominees include Mark A. Buthman, William F. Feehery, Robert F. Friel, Eric M. Green, Janet B. Haugen, Molly E. Joseph, Deborah L. V. Keller, Myla P. Lai-Goldman, Stephen H. Lockhart, Douglas A. Michels, and Paolo Pucci, all receiving majority support.
Added in current filing · verify on EDGAR →
Proposal 3: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified as set forth below.
ForAgainstAbstain
58,509,1197,556,514127,689
Shareholders ratified the appointment of PricewaterhouseCoopers LLP as the company's auditor for fiscal 2026 with approximately 88% support. This represents continuity in the company's external audit relationship.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify